These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 14608129)

  • 1. Use of lepirudin during percutaneous vascular interventions in patients with heparin-induced thrombocytopenia.
    Cochran K; DeMartini TJ; Lewis BE; O Brien J; Steen LH; Grassman ED; Leya F
    J Invasive Cardiol; 2003 Nov; 15(11):617-21. PubMed ID: 14608129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination platelet glycoprotein IIb/IIIa receptor and lepirudin administration during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia.
    Pinto DS; Sperling RT; Tu TM; Cohen DJ; Carrozza JP
    Catheter Cardiovasc Interv; 2003 Jan; 58(1):65-8. PubMed ID: 12508198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial.
    Lincoff AM; Kleiman NS; Kereiakes DJ; Feit F; Bittl JA; Jackman JD; Sarembock IJ; Cohen DJ; Spriggs D; Ebrahimi R; Keren G; Carr J; Cohen EA; Betriu A; Desmet W; Rutsch W; Wilcox RG; de Feyter PJ; Vahanian A; Topol EJ;
    JAMA; 2004 Aug; 292(6):696-703. PubMed ID: 15304466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of clopidogrel pretreatment effect on the relative efficacy of bivalirudin with provisional glycoprotein IIb/IIIa blockade compared to heparin with routine glycoprotein IIb/IIIa blockade: a REPLACE-2 substudy.
    Saw J; Lincoff AM; DeSmet W; Betriu A; Rutsch W; Wilcox RG; Kleiman NS; Wolski K; Topol EJ;
    J Am Coll Cardiol; 2004 Sep; 44(6):1194-9. PubMed ID: 15364319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitors in drug-eluting stent implantations in the absence of acute myocardial infarction: clinical and economic results.
    Mishkel GJ; Moore AL; Markwell SJ; Ligon RW
    J Invasive Cardiol; 2007 Feb; 19(2):63-8. PubMed ID: 17268039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bivalirudin versus heparin and glycoprotein IIb/IIIa inhibition among patients with renal impairment undergoing percutaneous coronary intervention (a subanalysis of the REPLACE-2 trial).
    Chew DP; Lincoff AM; Gurm H; Wolski K; Cohen DJ; Henry T; Feit F; Topol EJ;
    Am J Cardiol; 2005 Mar; 95(5):581-5. PubMed ID: 15721095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic evaluation of bivalirudin with provisional glycoprotein IIB/IIIA inhibition versus heparin with routine glycoprotein IIB/IIIA inhibition for percutaneous coronary intervention: results from the REPLACE-2 trial.
    Cohen DJ; Lincoff AM; Lavelle TA; Chen HL; Bakhai A; Berezin RH; Jackman D; Sarembock IJ; Topol EJ
    J Am Coll Cardiol; 2004 Nov; 44(9):1792-800. PubMed ID: 15519009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A safety and feasibility report of combined direct thrombin and GP IIb/IIIa inhibition with bivalirudin and tirofiban in peripheral vascular disease intervention: treating critical limb ischemia like acute coronary syndrome.
    Allie DE; Hebert CJ; Lirtzman MD; Wyatt CH; Keller VA; Khan MH; Khan MA; Fail PS; Vivekananthan K; Allie SE; Mitran EV; Chaisson G; Stagg SJ; Allie AA; McElderry MW; Barker EA; Walker CM
    J Invasive Cardiol; 2005 Aug; 17(8):427-32. PubMed ID: 16079449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial.
    Stone GW; White HD; Ohman EM; Bertrand ME; Lincoff AM; McLaurin BT; Cox DA; Pocock SJ; Ware JH; Feit F; Colombo A; Manoukian SV; Lansky AJ; Mehran R; Moses JW;
    Lancet; 2007 Mar; 369(9565):907-19. PubMed ID: 17368152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-molecular-weight heparin and other antithrombotic agents in the setting of a fast-track revascularization in unstable coronary artery disease.
    Bassand JP
    Haemostasis; 2000; 30 Suppl 2():114-21; discussion 106-7. PubMed ID: 11251354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Heparin-induced thrombocytopenia type II with early aortocoronary bypass occlusion and stent thrombosis after PTCA of the RCA--treatment with lepirudin (Refludan) and abciximab (Reo pro) during recanalization of the RCA].
    Laubenthal FC; Grosch B; Szurawitzki G; Sabin GV
    Z Kardiol; 1999 Feb; 88(2):141-6. PubMed ID: 10209835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical experience with combined treatment of thrombin inhibitors and GPIIb/IIIa inhibitors in patients with HIT.
    Walenga JM; Jeske WP; Wallis DE; Bakhos M; Lewis BE; Leya F; Fareed J
    Semin Thromb Hemost; 1999; 25 Suppl 1():77-81. PubMed ID: 10357156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial.
    Stone GW; Ware JH; Bertrand ME; Lincoff AM; Moses JW; Ohman EM; White HD; Feit F; Colombo A; McLaurin BT; Cox DA; Manoukian SV; Fahy M; Clayton TC; Mehran R; Pocock SJ;
    JAMA; 2007 Dec; 298(21):2497-506. PubMed ID: 18056903
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjunctive therapies in the cath lab. Use of combination glycoprotein IIb/IIIa inhibitor and direct thrombin inhibitor drugs to support percutaneous coronary stent placement in a patient with renal insufficiency and heparin-induced thrombocytopenia.
    Caputo RP; Giambartolomei A; Simons A; Reger M; Wagner S; Esente P
    J Invasive Cardiol; 2001 Sep; 13(9):657-60. PubMed ID: 11533507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utilization of GP IIb/IIIa inhibitors in peripheral percutaneous interventions: current applications and in-hospital outcomes at a tertiary referral center.
    Shammas NW; Dippel EJ; Shammas GA; Kumar A; Jerin M; Kennedy L
    J Invasive Cardiol; 2008 Jun; 20(6):266-9. PubMed ID: 18523317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study.
    Ferguson JJ; Antman EM; Bates ER; Cohen M; Every NR; Harrington RA; Pepine CJ; Theroux P;
    Am Heart J; 2003 Oct; 146(4):628-34. PubMed ID: 14564315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Direct thrombin inhibition appears to be a safe and effective anticoagulant for percutaneous bypass graft interventions.
    Kao J; Lincoff AM; Topol EJ; Madrid A; J Price M; Sawhney N; Teirstein PS
    Catheter Cardiovasc Interv; 2006 Sep; 68(3):352-6. PubMed ID: 16892428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization.
    Topol EJ; Moliterno DJ; Herrmann HC; Powers ER; Grines CL; Cohen DJ; Cohen EA; Bertrand M; Neumann FJ; Stone GW; DiBattiste PM; Demopoulos L;
    N Engl J Med; 2001 Jun; 344(25):1888-94. PubMed ID: 11419425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lepirudin as a safe alternative for effective anticoagulation in patients with known heparin-induced thrombocytopenia undergoing percutaneous coronary intervention: case reports.
    Manfredi JA; Wall RP; Sane DC; Braden GA
    Catheter Cardiovasc Interv; 2001 Apr; 52(4):468-72. PubMed ID: 11285599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Platelet glycoprotein IIb/IIIa inhibitors in coronary artery disease].
    Auer J; Berent R; Lassnig E; Weber T; Maurer E; Eber B
    Herz; 2003 Aug; 28(5):393-403. PubMed ID: 12928738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.